Investigate Role Of Metabolic Imaging In Predicting Tumor Response/Outcome After Pancreatic CA Tx

Study Overview

Investigate Role of Metabolic Imaging in Predicting Tumor Response/Outcome After Pancreatic CA Tx

To test the ability of new imaging techniques to monitor and predict response of pancreatic cancer to radiation and/or chemotherapy.

N/A

Pancreatic Cancer

PROCEDURE: PET Scan
DRUG: FLT
DRUG: FDG

PANC0004
95733
SU-11052007-795 (OTHER Identifier) (OTHER: Stanford University)

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates	Results Reporting Dates	Study Record Updates
First Submitted 2008-10-03	Results First Submitted N/A	Last Update Submitted that met QC Criteria 2012-06-07
First Submitted that Met QC Criteria 2008-10-06	Results First Submitted that Met QC Criteria N/A	Last Update Posted (ESTIMATED) 2012-06-11
First Posted (ESTIMATED) 2008-10-07	Results First Posted N/A	Last Verified 2012-06

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Diagnostic

Allocation:
Non Randomized

Interventional Model:
Single Group

Masking:
None

Arms and Interventions

Participant Group/Arm	Intervention/Treatment

Primary Outcome Measures	Measure Description	Time Frame
Evaluate the performance of the novel imaging methods

Secondary Outcome Measures	Measure Description	Time Frame
Correlate FLT activity with clinical outcomes

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

Negative urine pregnancy test if a woman of child-bearing potential (WOCBP).
WOCBP must be using an adequate method of contraception to avoid pregnancy throughout the study period.
All patients will be evaluated in a uniform manner at the Stanford GI Combined Modality Tumor Board to determine eligibility. Exclusion Criteria:1. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

PRINCIPAL_INVESTIGATOR: Albert Koong, Stanford University

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

Learn

Resources

PatientS

Caregivers

Clinical Trial Record